Asset overview
Program snapshot
Target: Unknown
Cell type: Unknown
Indications: Neoplasms
Sponsor: GlaxoSmithKline
Institution: GlaxoSmithKline
Adoptive Cell Therapy
Screening Platform
Screening Platform is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at GlaxoSmithKline, with a possible patent signal linked through modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Phase2
Status: Terminated
Trial count: 1
Active trials: 0
First posted: October 29, 2021
Last updated: February 5, 2024
Signal summary
IP and BD posture
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation1
IP linkage3
Licensing clarity2
Strategic interest0
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT05100316